P-glycoprotein (P-gp) is a well-known membrane transporter responsible for the efflux of an ample spectrum of anticancer drugs. Its relevance in the management of cancer chemotherapy is increased in view of its high expression in cancer stem cells (CSCs), a population of cancer cells with strong tumour-promoting ability. In the present study, a series of compounds were synthesized through structure modulation of MC70 ([4'-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol]), modifying the phenolic group of the lead compound. Among them compound 5b emerged for its activity against the transporter (EC50 = 15 nM) and was capable of restoring Doxorubicin anti-proliferative activity at non-toxic concentration. Its behaviour was rationalized through a molecular modelling study consisting of a well-tempered metadynamics simulation, that allowed to identify the most favourable binding pose, and of a subsequent molecular dynamics run which indicated a peculiar effect of the compound on the motion pattern of the transporter.

Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells

Riganti, Chiara
First
;
Guglielmo, Stefano
;
Salaroglio, Iris C.;Milosevic, Vladan;Rolando, Barbara;Lazzarato, Loretta;Fruttero, Roberta
2019-01-01

Abstract

P-glycoprotein (P-gp) is a well-known membrane transporter responsible for the efflux of an ample spectrum of anticancer drugs. Its relevance in the management of cancer chemotherapy is increased in view of its high expression in cancer stem cells (CSCs), a population of cancer cells with strong tumour-promoting ability. In the present study, a series of compounds were synthesized through structure modulation of MC70 ([4'-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol]), modifying the phenolic group of the lead compound. Among them compound 5b emerged for its activity against the transporter (EC50 = 15 nM) and was capable of restoring Doxorubicin anti-proliferative activity at non-toxic concentration. Its behaviour was rationalized through a molecular modelling study consisting of a well-tempered metadynamics simulation, that allowed to identify the most favourable binding pose, and of a subsequent molecular dynamics run which indicated a peculiar effect of the compound on the motion pattern of the transporter.
2019
62
2
974
986
http://pubs.acs.org/jmc
Molecular Medicine; Drug Discovery3003 Pharmaceutical Science
Riganti, Chiara; Contino, Marialessandra*; Guglielmo, Stefano; Perrone, Maria G.; Salaroglio, Iris C.; Milosevic, Vladan; Giampietro, Roberta; Leonetti, Francesco; Rolando, Barbara; Lazzarato, Loretta; Colabufo, Nicola A.; Fruttero, Roberta
File in questo prodotto:
File Dimensione Formato  
Riganti Postprint JMC 2019.pdf

Accesso riservato

Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 3.31 MB
Formato Adobe PDF
3.31 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Riganti, JMC MS and SI 2019.pdf

Accesso riservato

Descrizione: Riganti, JMedChem MS and SI 2019
Tipo di file: PDF EDITORIALE
Dimensione 3.03 MB
Formato Adobe PDF
3.03 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
2019_pgpsolfonamidi_JMC.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 8.8 MB
Formato Adobe PDF
8.8 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
handle_23181697822.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.9 MB
Formato Adobe PDF
1.9 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1697822
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact